AC
SPRB

Almitas Capital’s Spruce Biosciences SPRB Stock Holding History

Almitas Capital’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5,287
Closed -$188K – 106
2024
Q3 		$188K Hold
5,287
– – 0.07% 65
2024
Q2 		$205K Buy
+5,287
New +$283K 0.09% 70

Other funds holding SPRB

CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Almitas Capital's SPRB Position: Q4 2024 in Review

Almitas Capital sold out of Spruce Biosciences (SPRB) in Q4 2024, closing a stake of 5,287 shares — an estimated $188K sold.

Almitas Capital first reported a position in SPRB in Q2 2024 and held it in 2 quarters. The position peaked at $205K in Q2 2024. 31 funds tracked by Wall St. Rank hold SPRB as of Q4 2024.

  • Almitas Capital reported no remaining Spruce Biosciences position as of Q4 2024 after selling out during the quarter.
  • Almitas Capital sold 5,287 Spruce Biosciences shares in Q4 2024, an estimated $188K.
  • Almitas Capital first reported a position in Spruce Biosciences in Q2 2024 and held it in 2 quarters.
  • Almitas Capital's Spruce Biosciences position peaked at $205K in Q2 2024.
  • 31 funds tracked by Wall St. Rank held Spruce Biosciences as of Q4 2024.

Based on Almitas Capital's 13F filing for Q4 2024, filed 14 Feb 2025.